Journal Mobile Options
Table of Contents
Vol. 29, No. 6, 2008
Issue release date: January 2009

Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as Tumor Markers in Patients with Lung Cancer: Comparison with CYFRA 21-1, CEA, SCC and NSE

Molina R. · Auge J.M. · Escudero J.M. · Marrades R. · Viñolas N. · Carcereny E. · Ramirez J. · Filella X.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Tumor marker serum levels were prospectively studied in 289 patients with suspected, but unconfirmed, lung cancer and in 513 patients with lung cancer [417 non-small cell lung cancer (NSCLC) patients and 96 small cell lung cancer (SCLC) patients]. In patients with benign disease, abnormal serum levels were found for the following tumor markers: CEA (in 6.6% of patients); CA 19.9 (6.2%); CA 125 (28.7%); NSE (0.7%); CYFRA (8.7%); TAG-72.3 (4.2%); SCC (3.5%), and CA 15.3 (3.5%). Excluding patients with renal failure or liver diseases, tumor marker specificity improved with abnormal levels in 0.5% for NSE, 0.9% for SCC, 2.8% for CEA, CA 15.3 and TAG-72.3, 3.8% for CA 19.9, 4.2% for CYFRA and 21.4% for CA 125. Excluding CA 125, one of the markers was abnormal in 15% of patients without malignancy. Tumor marker sensitivity was related to cancer histology and tumor extension. NSE had the highest sensitivity in SCLC and CYFRA and CEA in NSCLC. Significantly higher concentrations of CEA, SCC, CA 125, CA 15.3 and TAG-72.3 were found in NSCLC than in SCLC. Likewise, significantly higher CEA (p < 0.0001), TAG-72.3 (p < 0.001), CA 15.3 (p < 0.0001) and CA 125 (p < 0.01) were found in adenocarcinomas than in squamous tumors. Using a combination of 3 tumor markers (CEA, CYFRA 21-1 in all histologies, SCC in squamous tumors and CA 15.3 in adenocarcinomas), a high sensitivity may be achieved in all histological types. Tumor markers may be useful in the histological differentiation of NSCLC and SCLC. Using specific criteria for the differentiation of SCLC and NSCLC, the sensitivity was 84.2 and 68.8%, the specificity was 93.8 and 99.7%, the positive predictive value was 98.3 and 98.5% and the negative predictive value was 57.7 and 93.3%, respectively.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics 2000. CA Cancer J Clin 2000;50:7–33.
  2. Schiller JH: Current standards of care in small-cell and non-small-cell lung cancer. Oncology 2001;61:3–13.
  3. Stupp R, Monnerat C, Turrisi AT, Perry MC, Leyvraz S: Small cell lung cancer: state of the art and future perspectives. Lung Cancer 2004;45:105–117.
  4. Spira A, Ettinger DS: Multidisciplinary management of lung cancer. N Engl J Med 2004;350:379–392.
  5. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olad J, Stover D, Strawn JR, Turrisi AT, Somerfield MR: American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330–353.
  6. Jorgensen LG, Osterlind K, Genolla J, et al: Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres. Br J Cancer 1996;74:463–467.
  7. Quoix E, Purohit A, Faller-Beau M, Moreau L, Oster JP, Pauli G: Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer 2000;30:127–134.
  8. Pujol JL, Quantin X, Jacot M, Boher JM, Grenier J, Lamy PJ: Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. Lung Cancer 2003;39:131–138.
  9. Molina R, Filella X, Auge JM: ProGRP: a new biomarker for small cell lung cancer. Clinical Biochem 2004;37:505–511.
  10. Shibayama T, Ueoka H, Nishii K, Kiura K, Tabata M, Miyatake Y, Harada M: Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small cell lung cancer (SCLC). Lung Cancer 2001;32:61–69.
  11. Stieber P, Hasholzner U, Bodenmüller H, Nagel D, Sunder-Plassmann L, Dienemann H, et al: CYFRA 21-1: a new marker in lung cancer. Cancer 1993;72(suppl):707–713.

    External Resources

  12. Niklinski J, Burzykowski T, Niklinska W, Laudanski J, Chyczewski L, Rapellino M, Furman M: Preoperative CYFRA 21.1 levels as a prognostic indicator in resected non-small cell lung cancer. Eur Respir J 1998;12:1424–1428.
  13. Wieskopf B, Demangeat C, Purohit A, Stenger R, Gries P, Kreisman H, et al: CYFRA 21-1 as a biologic marker of non-small cell lung cancer. Chest 1995;108/1:163–169.

    External Resources

  14. Molina R, Filella X, Torres MD, et al: SCC antigen measured in malignant and nonmalignant diseases. Clin Chem 1990;36:251–254.
  15. Pastor A, Menendez R, Cremades MJ, Pastor V, Llopis R, Aznar J: Diagnostic value of SCC, CEA and CYFRA 21-1 in lung cancer: a Bayesian analysis. Eur Resp J 1997;10:603–609.
  16. Buccheri G, Ferrigno D, Vola F: Carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA) and other prognostic indicators in squamous cell lung cancer. Lung cancer 1993;10:21–33.
  17. Nisman B, Heching N, Barak V: Serum tumor markers in resectable and non-resectable non-small cell lung cancer. J Tumor Marker Oncol 2000;15:195–207.
  18. Molina R, Agusti C, Mañe JM, Filella X, Jo J, Joseph J, Giménez N, Estapé J, Ballesta AM: CYFRA 21.1 in lung cancer: comparison with CEA, CA 125, SCC and NSE serum levels. Int J Biol Markers 1994;9:96–101.
  19. Molina R, Filella X, Augé JM, Fuentes R, Bover I, Rifa J, Moreno V, Canals E, Viñolas N, Marquez A, Barreiro E, Borras J, Viladiu P: Tumour markers (CEA, CA125, CYFRA 21-1, SCC and NSE) in NSCLC patients as aid in histological diagnosis and prognosis: comparison with the main clinical, pathological and anthropomorphic prognostic factors. Tumor Biol 2003;24:209–218.
  20. Keller T, Bitterlich N, Hilfenhaus S, Bigl H, Leohardt P: Tumour markers in the diagnosis of bronchial carcinoma: new options using fuzzy logic-based tumour marker profile. J Cancer Res Clin Oncol 1998;124:565–574.
  21. Scheulen ME, Klanig H, Wiefelspÿtz JK, Kšmper P, Wagner B, Konietzko N, et al: Pre-therapeutic evaluation of cytokeratin fragment 19 (CYFRA 21-1) in 240 patients with lung cancer in comparison to CEA, NSE, SCC-Ag, TPA and TPS. Tumor Diagn Ther 1997;18:14–19.
  22. Seregni E, Foa P, Bogni A, Botti C, Cataldo I, Sala M, et al: Evaluation of the soluble fragments of cytokeratin 19 (CK19) in non-small cell lung cancer (NSCLC): comparison with TPA, CEA, SCC and NSE. Oncol Reports 1996;3:95–101.

    External Resources

  23. Pujol JL, Grenier J, Parrat E, Lehmann M, Lafontaine T, Quantin X, et al: Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS. Am J Respir Crit Care Med 1996;154:725–733.
  24. Plebani M, Basso D, Navaglia F, De Paoli M, Tommasini A, Cipriani A: Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results? Br J Cancer 1995;72:170–173.
  25. European Group on Tumor Markers: Consensus recommendations. Anticancer Res 1999;19:2785–2820.
  26. Schneider J, Bitterlich N, Velcovsky HG, Morr H, Katz N, Eigenbrodt E: Fuzzy logic-based tumor-marker profiles improved sensitivity in the diagnosis of lung cancer. Int J Clin Oncol 2002;7:145–151.
  27. Eberth W, Muley TH: CYFRA 21.1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy. Anticancer Res 1999;19:2669–2672.
  28. Sieber P, Zimmermann A, Reinmiedl J, Muller C, Hoffman H, Dienemann H: CYFRA 21.1 in the early diagnosis of recurrent disease in non small cell lung carcinomas (NSCLC). Anticancer Res 1999;19:2665–2668.
  29. Kao CH, Hsieh JF, Ho YJ, Ding HJ: Cytoqueratin fragment 19 (CYFRA 21-1) and carcinoembryonic antigen for early prediction of recurrence of lung adenocarcinoma. Lung 1999;177:333–337.
  30. Bidart JM, Thuillier F, Augerearu C, Chalas J, Daver A, Jacob N, Labrousse F, Voitot H: Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem 1999;45:1695–1707.
  31. Nisman B, Amir G, Lafair J, Heching N, Lyass O, Peretz T, Barak V: Prognostic value of CYFRA 21.1, TPS, and CEA in different histologic types of non-small cell lung cancer. Anticancer Res 1999;19:3549–3552.
  32. Niklinski J, Furman M, Laudanski J, Kozlowski M: Prognostic value of pretreatment CEA, SCC-Ag and CA 19-9 levels in sera of patients with non-small cell lung cancer. Eur J Cancer Prev 1992;1:401–406.
  33. Diez M, Torres A, Maestro ML, Gomez A, Pollan M, Lopez JA, Picardo A, Hernando F, Balibrea JL: Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA 125 and SCC antigens in resectable non-small cell lung cancer. Br J Cancer 1996;73:1248–1254.
  34. Homma-S, Satoh-H, Kagohashi-K, Fujiwara-M, Kamma-H, Sekizawa-K: Production of CA125 by human lung cancer cell lines. Clin Exp Med 2004;4:139–141.
  35. Mountain CF: The international system for staging lung cancer. Semin Surg Oncol 2000;18:106–115.
  36. Stahel RA, Ginsberg R, Haveman K, Havemann K, Hirsch FR, Ihde DC, Jassem J: Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer 1989;5:119–126.

    External Resources

  37. Molina R, Filella X, Torres MD, et al: Evaluation of a new tumor marker, SCC in benign and neoplasic diseases. Clin Chem 1990;36:251–254.
  38. Molina R, Filella X, Bruix J, et al: Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem 1991;37:1379–1383.
  39. Cases A, Filella X, Molina R, Ballesta AM, López-Revert J, Revert L: Tumor markers in chronic renal failure and hemodialysis patients. Nephron 1991;57:183–186.
  40. Duffy MJ: CA19-9 as a marker for gastrointestinal cancers: a review. Ann Clin Biochem 1998;35:364–370.
  41. Molina R, Agustí C, Filella X, Jo J, Joseph J, Giménez N, Ballesta AM: Study of a new tumor marker, CYFRA 21-1 in malignant and nonmalignant diseases. Tumor Biol 1994;15:318–321.
  42. Semjonov A, Albrecht W, Bialk P, et al: Tumour markers in prostatic cancer: EGTM recommendations. Anticancer Res 1999;19:2785–2820.
  43. Filella X, Alcover J, Molina R, Rodriguez A, Carretero P, Ballesta AM: Clinical evaluation of fPSA/PSA ratio in the diagnosis of prostate cancer. Eur J Cancer 1997;33:1226–1229.
  44. Molina R, Barak V, van Dalen A, et al: Tumor markers in breast cancer: European Group on Tumor Markers recommendations. Tumor Biol 2005;26:281–293.
  45. Borras G, Molina R, Xercavins J, Ballesta A, Iglesias J: Tumor antigens CA 19.9, CA 125 and CEA in carcinoma of the uterine cervix. Gynecol Oncol 1995;57:205–211.
  46. Bonfrer JMG, Duffy MJ, Radtke O, et al: Tumour markers in gynaecological cancers: EGTM recommendations. Anticancer Res 1999;19:2807–2810.
  47. Gonzalez AM, Encabo G, Bermejo B, Armengol M: Prognostic value of the glycoprotein TAG-72.3 in patients with gastric cancer. Int J Biol Markers 2001;16:121–125.

    External Resources

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50